Nasdaq Trda News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq trda. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Trda Today - Breaking & Trending Today

Entrada Therapeutics, Inc. (NASDAQ:TRDA) CEO Sells $15,990.00 in Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report) CEO Dipal Doshi sold 1,000 shares of Entrada Therapeutics stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $15.99, for a total transaction of $15,990.00. Following the completion of the transaction, the chief executive officer now directly […] ....

New Zealand General , New Zealand , Dipal Doshi , Wellington Management Group , Securities Exchange Commission , Vanguard Group Inc , Entrada Therapeutics Inc , Blackrock Inc , Pricet Rowe Associates Inc , Entrada Therapeutics , Get Free Report , Exchange Commission , Therapeutics Stock Down , Management Group , Entrada Therapeutics Daily , Nasdaq Trda , Insider Trading , Nsider Trades ,

Kory James Wentworth Sells 10,206 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report) CFO Kory James Wentworth sold 10,206 shares of the stock in a transaction on Friday, December 22nd. The shares were sold at an average price of $15.69, for a total value of $160,132.14. Following the sale, the chief financial officer now owns 49,571 shares in the company, […] ....

Kory James Wentworth , Ameritas Investment Partners Inc , Entrada Therapeutics Inc , Tower Research Capital , Royal Bank , Lazard Asset Management , Entrada Therapeutics , Get Free Report , James Wentworth , Investment Partners , Asset Management , Research Capital , Strs Ohio , Entrada Therapeutics Daily , Nasdaq Trda , Insider Trading , Nsider Trades ,

Entrada Therapeutics (NASDAQ:TRDA) Price Target Lowered to $20.00 at HC Wainwright

Entrada Therapeutics (NASDAQ:TRDA – Free Report) had its price objective reduced by HC Wainwright from $25.00 to $20.00 in a research report released on Monday morning, Benzinga reports. They currently have a buy rating on the stock. Entrada Therapeutics Stock Performance Shares of NASDAQ:TRDA opened at $12.97 on Monday. The firm has a market capitalization […] ....

Northern Trust Corp , Charles Schwab Investment Management Inc , York Mellon Corp , Entrada Therapeutics Inc , Nan Fung Group Holdings Ltd , Vanguard Group Inc , Entrada Therapeutics , Free Report , Get Free Report , New York Mellon Corp , Schwab Investment Management , Trust Corp , Entrada Therapeutics Daily , Nasdaq Trda , Lower Price Target , Hc Wainwright ,

Entrada Therapeutics (NASDAQ:TRDA) Shares Gap Down to $16.67

Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report)’s share price gapped down before the market opened on Wednesday . The stock had previously closed at $16.67, but opened at $15.90. Entrada Therapeutics shares last traded at $15.47, with a volume of 5,380 shares. Analyst Upgrades and Downgrades Separately, HC Wainwright reiterated a “buy” rating and […] ....

New Zealand General , New Zealand , Entrada Therapeutics Inc , Wellington Management Group , Blackrock Inc , Pricet Rowe Associates Inc , Vanguard Group Inc , Entrada Therapeutics Company Profile , Entrada Therapeutics , Get Free Report , Management Group , Vanguard Group , Entrada Therapeutics Daily , Nasdaq Trda ,